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1. Introduction
Malignancies associated with the upper gastrointestinal (GI) tract are reported to be ex‐
tremely lethal. Most patients with gastric cancer (GC) in the United States are symptomatic
and already have complex untreatable disease at the time of presentation. GC in general, is a
senile malignancy (cancer of the aged) and is reportedly twice as common in blacks as in
whites. Routine screening is not extensively performed, except in countries, which have a
very high incidence of GC, such as Japan, Venezuela, and Chile. The three most common
primary malignant gastric neoplasms are adenocarcinoma (95%), lymphoma (4%), and ma‐
lignant GIST (Gastrointestinal stromal tumor)(1%). Fortunately, dedicated research into its
pathogenesis and detection of new risk factors, treatment, and advanced endoscopic techni‐
ques have led to early diagnosis of GC in the modern era.
2. Adenocarcinoma
Adenocarcinoma of the gastric epithelium is the most common form of malignancies of the
gut (90% of cases). Carcinoma of the connective tissue (sarcoma) and lymphatics (lympho‐
ma) is reportedly less common. Adenocarcinomas (Figures 1, 2) most commonly occur in the
gastric cardia (31%), followed by the antrum (26%), and body of the stomach (14%). The 5-
year overall survival rate is 25.7%, which has not changed drastically over the past 30 to 40
years. Surgery remains the mainstay of treatment for GC, the survival can be improved with
multimodal approach.
© 2013 Kumar et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. Showing A. CT image of Linitis plastic (arrows denotes a thickened gastric wall). B. endoscopic image. C. illus‐
tration of linits plastic. Picture courtesy: John Hopkins Medicine- Gastroenterology and Hepatology department. ‘An
introduction to Gastric cancer’, 2012.
Figure 2. Showing A. the Endoscopic image of an ulcerating adenocarcinoma. B. Ulcerating adenocarcinoma, pictorial
representation. Picture courtesy: John Hopkins Medicine- Gastroenterology and Hepatology department. ‘An intro‐
duction to Gastric cancer’, 2012.
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2.1. Incidence and prevalence
GC is one of the most common cancers worldwide, causing almost 738,000 deaths annually.
The incidence of GC varies widely, both globaly and within individual country. High-inci‐
dence has been reported from parts of Latin America, Eastern Asia, Europe and the Middle
East [1]. The overall incidence rates are different, but they are increased among certain eth‐
nic and racial groups, such as Hispanics and African-Americans [2] in the US. More recently,
for reasons unknown, a growing rate in the incidence of GC has been reported among
young adults in the US [3]. The incidence of early GC (EGC), as well as the percentage of
gastric adenocarcinomas that are EGCs, vary depending on the population: In Japan and
Eastern Asia, up to one-half of resections for gastric adenocarcinoma represent EGC. In Ja‐
pan, the proportion rose from 15 to as high as 57 percent with the introduction of routine
screening programs; In Korea, 25 to 30 percent of gastric adenocarcinomas are EGCs [4]; In
Western countries, EGCs account for 15 to 21 percent of gastric adenocarcinomas [4]
GC tends to occur 1.5 to 2.5 times more frequently in African Americans, Hispanic Ameri‐
cans, and Native Americans than whites. GC occurs at a median age of 69 years for men and
73 for women [5], and has an elevated incidence in groups of lower socioeconomic status. In
the US, an estimated 21,130 new cases of GC were diagnosed in 2009, with 10,620 deaths [2].
According to the Surveillance Epidemiology and End Results (SEER) [5] (2000–2006) data‐
base, only 24% of GCs are confined to the stomach (localized); 31 to 32% of newly diagnosed
cases have spread beyond the stomach into the peripheral lymph nodes (regional) or other
organs (distant), respectively [5]. GC predominantly affects men compared to women, at a
ratio of 2:1. On the basis of SEER 2002-2006 data, the age-adjusted incidence of GC is 7.9 per
100,000 men and women per year [5]. In younger patients, tumors are more often of the dif‐
fuse variety and tend to be large, aggressive, and more poorly differentiated, sometimes in‐
filtrating the entire stomach (linitis plastica). The 5-year OS (overall survival) rate is 25.7%,
which has not changed significantly over the past 30 to 40 years [5]. Surgical intervention is
still the only available option to effectively cure GC, and endurance could be improved with
multimodal therapy.
2.2. Etiology
Gastric adenocarcinoma is a multifactorial disease. It is observed that when people migrate
from a place with high incidence to a place with low incidence the occurrence of cancer in
new generations is lesser. This suggests an unknown environmental factor contributing to
the development of GC. It is widely believed that consumption of salt-preserved and
smoked food is associated with onset of GC. Achlorhydric stomach predisposes to growth of
bacteria wherein nitrate is converted into nitrite, a proven carcinogen. Bacteria may be intro‐
duced exogenously through the ingestion of partially decayed foods, which are consumed
generously worldwide by the lower socioeconomic classes. Serial endoscopic examinations
of the stomach in patients with atrophic gastritis have documented replacement of the usual
gastric mucosa by intestinal-type cells. This process of intestinal metaplasia may lead to cel‐
lular atypia and eventual neoplasia. The theoretical sequence of development of gastric ade‐
nocarcinoma is illustrated in figure 3 [7].
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Figure 3. Showing the sequence of development of GC (Adopted from: Swartz’s principles of surgery, 9th edition, Sep‐
tember 2009).
2.3. Helicobacter pylori [7, 8]
Helicobacter pylori  has been classified as a group 1 (i.e. definite) carcinogen by the World
Health organization (WHO) report. Recent lines of evidence showed that persistent H.pylo‐
ri infection increases the risk of GC in patients to about three-fold. Patients with history of
gastric ulcers are more likely to develop GC as compared to uninfected individuals, (inci‐
dence ratio 1.8, 95% confidence interval 1.6 to 2.0), and patients with a history of duode‐
nal  ulcer  are  at  decreased risk  for  GC (incidence ratio  0.6,  95% CI  0.4  to  0.7).  H. pylori
causes chronic gastritis, loss of gastric acidity, and bacterial growth in the gastric antrum.
The effect of H. pylori eradication on the subsequent risk for GC in high-incidence areas is
under investigation.
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2.4. Epstein-Barr virus
EBV, a virus belonging to the herpesviridae family of DNA viruses is reported to be associ‐
ated with the development of late stages of cancer. EBV accounts for ~10% of all GCs.
2.5. Genetic factors
Numerous genetic abnormalities have been implicated in the development of GC, and most
of them are aneuploid. Genetic abnormalities in the tumor suppressor gene p53, and COX-2
are the two most common causes observed among the sporadic cases of GC. More than two
thirds of GCs have deletion or suppression mutations in the p53 message.
2.6. Fruits, vegetables and fiber
Consumption of fruits and vegetables, especially fruits is believed to protect against GC.
Case-control studies from Europe, Asia, and North America have shown that intake of fruits
and vegetables could confer protection against GC, reducing the risk by ~40 percent for
fruits, and ~30 percent for vegetables for the highest versus lowest categories of intake, re‐
spectively. Diets low in vitamin C show the strongest association with GC. The protection
attributed to consumption of vegetables and fruits is most likely related to vitamin C con‐
tent, which is believed to lower the formation of carcinogenic N-nitroso compounds in the
gut. However, cooked vegetables do not show the equal degree of protection as uncooked
vegetables.
2.7. Other factors
Prospective investigations have highlighted the importance of intake of cereal fibers in alle‐
viating the risk of development of diffuse type GC, but not the intestinal type. Individuals
with blood group A are reported to develop ~20 percent increased risk of GC than those
with group O, B, or AB [6]. Interestingly, excessive body weight and obesity are associated
with an increased risk of development of GC [9]. According to a study, the strength of asso‐
ciation between body weight and cancer increased with increasing BMI. Several studies
have investigated the relationship between tobacco smoking and GC. A meta-analysis of 40
different investigations has estimated that the risk was increased by ~1.5 to 1.6-fold and was
higher in men. A prospective study found that, compared with non-smokers, active smokers
were at increased risk for cancer at the gastric cardia (HR 2.9, 95% CI 1.7, 4.7), and gastric
noncardia (HR 2.0, 95% CI 1.3, 3.2] [10]. Finally, regular use of NSAIDs has been inversely
associated with the risk of distal gastric adenocarcinoma [11, 12].
2.8. Premalignant conditions of the stomach
Certain premalignant conditions of the stomach are reported to predispose to the develop‐
ment of GC. A study conducted in Tokyo and Japan involving 1900 cases has shown that the
prevalence of certain premalignant conditions (figure 4) is associated with the development
of EGC.Atrophic gastritis is by far the most commonly reported precancerous condition of
the stomach predisposing to development of GC.
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Figure 4. Showing the premalignant lesions of the stomach (Source: Swartz’s principles of surgery, 9th edition. Sep‐
tember 2009)
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2.9. Molecular pathogenesis of GC
Almost half of the intestinal types of GCs is associated with mutations in tumor suppres‐
sor genes. TP53 is one key regulatory molecule that protects cells in the chronic inflamma‐
tory  stress  microenvironment,  and any event  leading to  the  loss  of  TP53  expression by
LOH (i.e. Loss Of Heterozygosity or mutational inactivation) culminates in frequent gas‐
tric alterations and development of GC, occurring in >60% of invasive tumors [13]. Anoth‐
er molecular factor associated with GC is the c-met oncogene expression that is reportedly
amplified in 19% of intestinal type and 39% of diffuse type of GCs. Especially, expression
of 6.0 kb c-met  transcript  is  associated with more advanced disease stage at  the time of
presentation. Likewise, there are other molecular mechanisms suggested for GC. k-ras mu‐
tations are detected in intestinal metaplasia, dysplasia and invasive cancers. TP73 is found
to be either overexpressed or not expressed at all.  Over expression of p73  and the onco‐
genic isoform Delta Np73 suppresses p73 transcriptional and apoptotic activity in gastroe‐
pithelial cancer cells and increases intracellular β-catenin levels, an effect that is inhibited
in the presence of wild-type but not mutant p53. Loss of expression has been reported via
epigenetic mechanisms in EBV-associated GCs [14]. Mutations in APC (adenomatous poly‐
posis coli)  gene are identified in significantly more intestinal-type than diffuse-type GCs
(33 versus  13  percent).  These  mutations  are  also  found in  H. pylori-associated dysplasia
and intestinal metaplasia [14]. Loss of TFF1 (trefoil factor family1) expression has been ob‐
served in intestinal metaplasia of the incomplete type and in GCs. The trefoil factor fami‐
ly (TFF) of proteins comprises a group of gastrointestinal peptides that are involved in the
protection of the mucous epithelium. Cell cycle regulatory molecules — Cyclin E and cy‐
clin-dependent kinase inhibitor 1B (CDKN1B, p27) are the two important cell-cycle regula‐
tors that take part in G1/S transition. Cyclin E overexpression is a frequent event in GCs,
and might  be  an indicator  for  malignant  transformation of  dysplasia,  and/or  tumor ag‐
gressiveness following development of  an invasive cancer.  E-cadherin,  a  key protein on
cell surfaces responsible for intercellular connections, is absent in diffuse type of carcino‐
ma enabling tumor cells to invade and metastasize.
2.10. Pathology
Dysplasia, the earliest stage in the development of cancer, is regarded as the precursor of
GC. Mildly dysplastic cases are followed up with endoscopic surveillance plus H.pylori erad‐
ication. Nonetheless, severely dysplastic cases need gastric resection if tumor is widespread
or multifocal; or may need Endoscopic Mucosal Resection (EMR) if the tumor is localized.
2.11. Early and late GC
Early GC is defined as adenocarcinoma limited to the mucosa and submucosa of the stom‐
ach, irrespective of lymph node status. Late GC defined as a gastric carcinoma that has in‐
vaded the muscle wall. It is the stage at which the tumor is commonly diagnosed in the US.
Different types of Early GCs (EGC) have been illustrated in figure 5.
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Figure 5. Different types of EGC (Source: Swartz’s principles of surgery, 9th edition, September 2009)
2.12. Gross morphology and histologic subtypes
Morphologically, there are four varieties of GCs: polypoid, fungating, ulcerative, and scir‐
rhous. In polypoidal and fungating, the bulk of the tumor mass is found intraluminally. In case
of ulcerative and scirrhous type the bulk of the tumor is found in the wall of the stomach.
Whilst polypoid type of tumors are not ulcerated, fungating tumors are elevated intraluminal‐
ly, and ulcerated. As the name implies, ulcerative variety morphologically resembles ulcers.
On contrary, the scirrhous tumors tend to infiltrate the entire thickness of the stomach and cov‐
er a very large surface area. Scirrhous tumors involve the entire stomach and have a very poor
prognosis. This is classically described as ‘Linitis plastica’ or leather bottle appearance which is
characterized by loss of distensibility of the gastric wall. Regarding the anatomic location of
GC, in the US, 30% of GCs originate in the distal, 20% arise in the mid portion, and 37% origi‐
nate in the proximal third of the stomach. The remaining 13% involve the entire stomach.
2.13. Histology
Histologic characterization of the GC is important as histologic type and the depth of inva‐
sion are the most important prognostic indicators. There are many histologic classifications
of GC. The histologic classification described by WHO involves: Adenocarcinoma (papil‐
lary, tubular, mucinous, signet-ring), adenosquamous, squamous, small cell, undifferentiat‐
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ed, and others. Further, there is a Japanese classification which is similar to the one
described by WHO, but more descriptive. There is also a Lauren classification which classi‐
fies GCs into intestinal (53%), diffuse (33%), and unclassified (14%) GC types.
2.14. Pathologic staging
Prognosis depends on the pathologic stage of the disease, and TNM (i.e. tumor-node-meta‐
stasis) (Table 1) staging is the most widely used system based on the depth of tumor inva‐
sion, extent of lymph node metastases [38], and presence of distant metastases. This system
was initially developed by the American Joint Committee on Cancer and the International
Union Against Cancer, and has undergone several modifications since then.
Primary tumor (T) Regional lymph nodes (N)
TX Primary tumor cannot be assessed NX Regional lymph node(s) cannot be assessed
T0 No evidence of primary tumor N0 No regional lymph node metastasis
Tis Carcinoma in situ: intraepithelial tumor without invasion of the lamina
propria
N1 Metastasis in 1-2 regional lymph nodes
T1 Tumor invades lamina propria, muscularis mucosae, or submucosa N2 Metastasis in 3-6 regional lymph nodes
T1a Tumor invades lamina propria or muscularis mucosae N3 Metastasis in seven or more regional lymph
nodes
T1b Tumor invades submucosa N3a Metastasis in 7-15 regional lymph nodes
T2 Tumor invades muscularispropria N3b Metastasis in 16 or more regional lymph nodes
T3 Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures
T4 Tumor invades serosa (visceral peritoneum) or adjacent structures Distant metastasis (M)
T4a Tumor invades serosa (visceral peritoneum) M0 No distant metastasis
T4b Tumor invades adjacent structures M1 Distant metastasis
Primary tumor (T) Regional lymph nodes (N)
TX Primary tumor cannot be assessed NX Regional lymph node(s) cannot be assessed
T0 No evidence of primary tumor N0 No regional lymph node metastasis
Tis Carcinoma in situ: intraepithelial tumor without invasion of the lamina
propria
N1 Metastasis in 1-2 regional lymph nodes
T1 Tumor invades lamina propria, muscularis mucosae, or submucosa N2 Metastasis in 3-6 regional lymph nodes
T1a Tumor invades lamina propria or muscularis mucosae N3 Metastasis in seven or more regional lymph
nodes
T1b Tumor invades submucosa N3a Metastasis in 7-15 regional lymph nodes
T2 Tumor invades muscularispropria N3b Metastasis in 16 or more regional lymph nodes
T3 Tumor penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures
T4 Tumor invades serosa (visceral peritoneum) or adjacent structures Distant metastasis (M)
T4a Tumor invades serosa (visceral peritoneum) M0 No distant metastasis
T4b Tumor invades adjacent structures M1 Distant metastasis
Table 1. TNM Classification for Gastric Cancer
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Stage T N M Stage T N M
0 Tis N0 M0
IIIA
T4a N1 M0
IA T1 N0 M0 T3 N2 M0
IB T2 N0 M0 T2 N3 M0T1 N1 M0
IIIB
T4b N0 M0
IIA
T3 N0 M0 T4b N1 M0
T2 N1 M0 T4a N2 M0
T1 N2 M0 T3 N3 M0
IIB
T4a N0 M0
IIIC
T4b N2 M0
T3 N1 M0 T4b N3 M0
T2 N2 M0 T4a N3 M0
T1 N3 M0 IV Any T Any N M1
A tumor may penetrate the muscularispropria with extension into the gastrocolic or gastrohepatic ligaments, or
into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures. In
this case, the tumor is classified T3. If there is perforation of the visceral peritoneum covering the gastric liga‐
ments or the omentum, the tumor should be classified T4.• The adjacent structures of the stomach include the
spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and
retroperitoneum.
Δ Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any
of these sites, including the stomach.
◊ A designation of pN0 should be used if all examined lymph nodes are negative, regardless of the total number
removed and examined.
Tables 1 & 2 Source: The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition
[2010] published by Springer New York, Inc.*
Table 2. Anatomic stage/prognostic groups
Criteria
1. High probability of en bloc resection
2. Tumor histology:
a. Intestinal type adenocarcinoma
b. Tumor confined to the mucosa
c. Absence of venous or lymphatic invasion
3. Tumor size and morphology:
a. Less than 20 mm in diameter, without ulceration
b. Less than 10 mm in diameter if Paris classification IIb or IIc
(Extended criteria)
4. Mucosal tumors of any size without ulceration
5. Mucosal tumors less than 30 mm with ulceration
6. Submucosal tumors less than 30 mm confined to the upper 0.5 mm of
the submucosa without lymphovascular invasion
Table 3. The criteria for EMR/ESD
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2.15. Spread
GC initially infiltrates the submucosa and invades through the muscle wall into the fat of
the omentum. Transcoelomic spread of the tumor cells is possible through peritoneal fluid
when serosa is involved. Such metastases may involve to rectovesical pouch or ovary (Kru‐
kenberg tumor). Microscopic satellite nodules may be formed some distance away from the
main mass by involvement through submucosal lymphatics. Lymphatic spread is responsi‐
ble for the involvement of the nodes around the stomach. Also, when tumor spreads to in‐
volve left supraclavicular nodes, it is known as Virchow’s nodes.
2.16. Clinical features
Most patients, who are diagnosed with GC in the US are in advanced stage III or IV disease
at the time of diagnosis. GCs, when surgically curable and superficial, usually produce no
symptoms. The clinical manifestations also depend on the anatomical location of the tumor.
Large tumors which are present in the fundus and body may simply manifest with occult
blood loss. In contrast, tumors of the antrum will delay gastric emptying and lead to anorex‐
ia, early satiety, and eventually the features of gastric outlet obstruction. Tumors of the
proximal stomach can also involve the distal esophagus and present with dysphagia. As the
cancer becomes more extensive, patients might complain of slight upper abdominal distress
varying in intensity from a vague, postprandial fullness to a severe, sturdy pain. Symptoms
are generally nonspecific and most frequently include abdominal pain, weight loss, nausea,
decreased food intake due to anorexia and early satiety. Weight loss consequences from in‐
adequate calorie intake rather than increased catabolism and may be attributable to nausea,
anorexia, abdominal pain, early satiety, and dysphagia.
Abdominal pain tends to be epigastric in nature. Dysphagia is a common symptom in can‐
cers involving proximal stomach or at the esophago-gastric junction. Other symptoms in‐
clude nausea, early satiety, symptoms of gastric outlet obstruction. Occult gastrointestinal
bleeding with or without iron deficiency anemia is not uncommon. Postprandial vomiting
suggests pyloric obstruction. Nearly 25% of patients have a history of gastric ulcer, stressing
the importance of eradication of H. pylori infection.
Patients may also present with signs or symptoms of distant metastatic disease. Since GC
can spread through lymphatics, the physical examination may reveal a left supraclavicular
adenopathy (a Virchow's node ) which is the most common physical examination finding of
metastatic disease, a periumbilical nodule (Sister Mary Joseph's node ), or a left axillary
node (Irish node). Peritoneal spread can present with an enlarged ovary (Krukenberg's tu‐
mor) or a mass in the cul-de-sac on rectal examination (Blumer's shelf). Ascites can also be
the initial indication of peritoneal carcinomatosis. A liver mass that can be palpable may in‐
dicate metastases. Paraneoplastic manifestations may include skin findings such as rapid
appearance of diffuse seborrheic keratoses (sign of Leser-Trelat) or acanthosis nigricans,
which is characterized by velvety and darkly pigmented patches on skin folds. Other signs
are: microangiopathic hemolytic anemia, membranous nephropathy, hypercoagulable states
(Trousseau's syndrome) and polyarteritis nodosa.
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2.17. Tumor markers and screening
There is no single marker that has been identified as the marker of GC. A study conducted
in Japan reported that screening program for GC has limited value. For the same reason,
there are no recommendations for screening the cancer. Some of the high risk factors have
been identified though. These include elderly patients with atrophic gastritis, pernicious
anemia, patients with partial gastrectomy, patients with FAP/HNPCC (familial adenoma‐
tous polyposis / hereditary nonpolyposis colorectal cancer), patients with sporadic gastric
adenoma. Periodic upper GI endoscopy can be of little benefit to those who are considered
to be at risk. Recently, KAI1/CD82 has been researched as a possible marker for the cancer,
but results are inconclusive [15]. Annexin II [16] and S100A6 proteins have shown promis‐
ing results in predicting prognosis as these two proteins are associated with tumor invasion,
metastasis, TNM stage and poor prognosis. Similarly PIWI protein and ADAM17 glycopro‐
tein correlate with cancer occurrence, development and metastasis [17, 18]
2.18. Serologic markers
Serum levels of carcinoembryonic antigen (CEA), the glycoprotein CA 125 antigen (CA 125],
CA 199, and CA 724 may be elevated in patients with GC [19, 20]. Nevertheless, low rates of
sensitivity and specificity stop the use of any of these serologic markers as diagnostic tests
for GC. Some GCs may mark elevated serum levels of α-fetoprotein (AFP); which are refer‐
red to as α-fetoprotein producing GCs [21-22]. A subset, hepatoid adenocarcinomas of the
stomach, has a histologic appearance that is analogous to that of HCC. Regardless of mor‐
phology, AFP-producing GCs are aggressive and associated with a poor prognosis.
2.19. Investigations and preoperative evaluation
• Patients >45 years of age who have new-onset dyspepsia, as well as all patients with heart
burn and alarm symptoms (dysphagia, weight loss, recurrent vomiting, evidence of
bleeding, or anemia) or with a family history of GC should have timely upper endoscopy
and biopsy if a mucosal lesion is noted by endoscope.
• All patients in whom GC is one of the differential diagnoses should undergo endoscopic
and biopsic procedures. If the biopsy is negative and suspicion for cancer is high, the pa‐
tient should be re-endoscoped and more aggressively biopsied.
• In some patients with gastric tumors, upper GI series can be useful in planning treatment.
Although a good double-contrast barium upper GI examination is sensitive for gastric tu‐
mors (up to 75% sensitive), endoscopy has become the gold standard for the diagnosis of
gastric malignancy.
2.20. Endoscopy
Tissue identification and anatomic localization of the primary tumor are best accomplished by
upper gastrointestinal endoscopy. The early usage of upper endoscopy in patients presenting
with gastrointestinal complaints may be related with a higher rate of finding of early GCs. En‐
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doscopy allows a close inspection of the mucosa, which is generally the only way to detect ear‐
ly GC. The presence of dysplasia, however, should always be regarded as significant because it
could be a sign of malignant transformation, or presence of adjacent malignancy.
The diagnosis of a particularly aggressive form of diffuse-type GC, called "linitis plastica",
can be cumbersome with endoscopy owing to the nature of these tumors to infiltrate into the
submucosa and muscularis propria, and hence, biopsies of superficial mucosal may be false
negative. For this reason, a combination of strip and bite biopsy technique should be used
when there is a suspicion of diffuse type GC.
2.21. Ultrasonography
Ultrasonography of the abdomen may be helpful for assessing the spread of GC. It may de‐
tect evidence of lymphadenopathy but can be particularly precious in detecting metastases
within the liver. A number of studies advocate that endoscopic ultrasound has an accuracy
of 90% in defining the depth of invasion within the stomach itself. It is also sensitive to wall
thickening and will detect diffuse carcinomas, and carcinomas associated with peripheral
lymph nodes.
2.22. Barium studies
Barium studies can make out both malignant gastric ulcers and infiltrating lesions. Howev‐
er, false-negative barium studies can occur in as many as 50% of cases. Thus, in most set‐
tings, upper endoscopy is the chosen initial diagnostic test for patients in whom GC is
suspected.
The only scenario where barium study may be superior to upper endoscopy is in patients with
linitis plastica. The decreased distensibility of the stiff, "leather-flask" appearing stomach is
more obvious on radiography, while the endoscopic image may appear relatively normal.
2.23. Positron emission tomography scanning
Whole-body PET scanning uses a principle whereby tumor cells preferentially amass posi‐
tron-emitting 18F-fluorodeoxyglucose. This modality is most helpful in the evaluation of dis‐
tant metastasis in GC but can also useful in loco-regional staging. PET scan is most useful
when combined with spiral CT (PET-CT) and should be considered before major surgery in
patients with predominantly high-risk tumors or multiple medical co morbidities.
2.24. Abdominopelvic CT scan
Dynamic computerized tomography (CT) imaging is generally performed early during pre‐
operative assessment after a diagnosis of GC is made. CT is widely available and noninva‐
sive. It is best suited in evaluating widely metastasized disease, especially hepatic or
adnexal metastases, ascites, or distant nodal spread. Patients who have CT-defined visceral
metastatic disease can evade unnecessary surgery, although biopsy confirmation is recom‐
mended because of the risk of false-positive findings. Peritoneal metastases and hematoge‐
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nous metastases smaller than 5 mm are often missed by CT, even using modern CT
techniques [23].
2.25. Endoscopic ultrasonography [24-27]
Endoscopic ultrasonography (EUS) is considered to be the most reliable nonsurgical method
available for evaluating the depth of invasion of primary gastric cancers, particularly for early
(T1) lesions. The precision of EUS for differentiation of individual tumor stages (T1 to T4) rang‐
es from 77 to 93%, with the experience of the operator markedly influencing these rates.
2.26. PET scan
The role of positron emission tomography (PET) using 18-fluorodeoxyglucose (FDG) in pre‐
operative staging of GC is rapidly developing. From the stand point of loco-regional stag‐
ing, integrated PET/CT imaging may assist in the confirmation of CT-detected malignant
lymphadenopathy [28]. The main advantage of PET is that it is more sensitive than CT for
the detection of distant metastases [29, 30]. An important caution is that the sensitivity of
PET scanning for peritoneal carcinomatosis is only approximately 50% [31]. Thus, PET is not
a satisfactory replacement for staging laparoscopy.
2.27. Chest imaging
A preoperative chest x-ray is recommended in patients with GC [32]. However, the sensitivi‐
ty for metastases is limited, and a chest CT scan is preferred (particularly for patients with a
proximal GC) if the detection of intrathoracic disease would modify the treatment plan.
2.28. Staging laparoscopy
Laparoscopy, while more invasive than CT or EUS, has the advantage of directly visualizing
the liver surface, the peritoneum, and local lymph nodes. Between 20 and 30 percent of pa‐
tients who have disease that is beyond T1 stage on EUS will be found to have peritoneal
metastases in spite of having a negative CT scan [34]. Particularly among patients with ad‐
vanced (T3 or 4) primary tumors, performance of a diagnostic laparoscopy may alter man‐
agement (typically by avoiding an unnecessary laparotomy) in up to one-half [35]. As noted
previously, the sensitivity of PET scans for the detection of peritoneal carcinomatosis is only
about 50%. Another advantage to laparoscopy is the chance to perform peritoneal cytology
in patients who have no visible evidence of peritoneal spread. In most (but not all) series
this is a poor prognostic sign, even in the absence of overt peritoneal dissemination, and
predicts for early peritoneal relapse. Diagnostic laparoscopy should also be performed in
patients who are being considered for neoadjuvant therapy.
2.29. Preoperative evaluation
The rationale of the preoperative evaluation is to primarily stratify patients into two clinical
groups: those with loco-regional, potentially resectable (stage I to III) disease and those with
systemic (stage IV) involvement.
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2.30. Treatment (EGC)
Treatment options available for early GC (EGC) are endoscopic resection, gastrectomy, anti‐
biotic therapy to eradicate H. pylori and adjuvant therapies. Endoscopic resection is achieved
either by endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD).
The criteria for EMR or ESD are outlined in the table: 2 [36, 37]:
Even though en bloc resection of the tumor mass has the ideal outcome following mucosal
resection, when it fails gastrectomy is the option. Gastrectomy is the most widely practiced
treatment modality for GC with a very high five-year survival rates [39-44]. Recently laparo‐
scopic gastrectomy is gaining popularity with high success rates observed in several centers
[40, 41, 45-50].
Anti-H.pylori therapy: As noted above, H. pylori is declared as a definite carcinogen. Its occur‐
rence is associated with cancer recurrence necessitating its eradication [51]. According to a
randomized trial and a case series, eradication of H. pylori following endoscopic resection of
EGC is found to be associated with reduced risk of metachronous cancers [52].
Adjuvant therapy: The adjuvant therapy with either systemic chemotherapy, radiotherapy, or
intraperitoneal chemotherapy following treatment for EGC is not completely established es‐
pecially for patients with node-negative cancer. On the other hand, for all patients with posi‐
tive nodes, adjuvant therapy is recommended irrespective of T stage.
2.31. Treatment of invasive GC
The only curative treatment for GC is surgical excision of tumorous mass [53, 54]. Usually
abdominal exploration is considered with the curative intent unless there is doubt regarding
dissemination, vascular invasion, patient has a medical contraindication for surgery, or a ne‐
oadjuvant therapy is considered.
Linitis plastica: In ~5 percent of GC, most of the stomach wall or sometimes the entire stom‐
ach wall is infiltrated by malignancy resulting in a rigid thickened wall called linitis plastica.
It is more prevalent in younger population [55]. Sometimes this form of cancer represents
spread from lobular breast cancer, and is associated with poor prognosis [56, 57]. As there
will be nodal involvement frequently, complete excision is the goal even though surgeons
consider it to be a contraindication to curative resection.
Total versus subtotal gastrectomy: Total gastrectomy is in vogue for the treatment of invasive
GC, even though endoscopic resection is performed for superficial cancers. To note, total
gastrectomy is indicated for lesions in the proximal (i.e. upper third) of the stomach, and
distal lesions (lower two-thirds) require subtotal gastrectomy with resection of adjacent
lymph nodes. Importantly, the patients presenting with large mid gastric or infiltrative le‐
sions like linitis plastica require total gastrectomy.
Proximal and esophagogastric junction tumors: The precise guidelines for surgical excision of
proximal tumors are complex. Those tumors that do not invade the esophagogastric junction
(EGJ) are managed by either a total or a proximal subtotal gastrectomy. Most surgeons pre‐
fer total gastrectomy for the following reasons: 1. The incidence of reflux esophagitis is ex‐
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tremely low following Roux-en-Y reconstruction performed during total gastrectomy
compared to those who have undergone proximal subtotal gastrectomy in whom roughly
one third patients had reflux esophagitis. 2. It is highly unlikely to remove the lymph nodes
along the lesser curvature following proximal subtotal gastrectomy. This may make the
metastases escape from surgery.
Degree of lymph node dissection: Again this is the controversial area in the surgical manage‐
ment of GC. Japanese surgeons routinely perform extended lymphadenectomy, which may
partially account for the better survival rates among Asian series as compared to Western
series [58]. 'Extended lymphadenectomy' refers to either a D2 or D3 nodal dissection.
D1, D2, and D3 terminologies: Japanese surgeons have divided the draining lymph nodes of
stomach into 16 stations: stations 1-6 are perigastric, remaining 10 are located side by the
major vessels, posterior to pancreas and along the aorta. D1 lymphadenectomy involves lim‐
ited dissection of only the perigastric lymph nodes. D2 lymphadenectomy involves extend‐
ed lymph node dissection encompassing removal of nodes along the hepatic, left gastric,
celiac and splenic arteries and splenic hilum (stations 1 to 11). D3 lymphadenectomy in‐
volves super extended lymph node dissection. In short it is the D2 lymphadenectomy along
with resection of nodes within portahepatis and periaortic regions (referred to as stations 1
to 16). Others use the term to denote a D2 dissection plus periaortic nodal dissection
(PAND) [59].
Factors in favor of extended lymphadenectomy are, removing more number of nodes accu‐
rately stages the disease extent and failure to remove these nodes leaves behind the disease
in nearly one third of patients [60]. This would explain the better stage specific survival rates
in Asian patients.
Factors against the extended lymphadenectomy are, higher incidence of associated morbidi‐
ty and mortality especially if splenectomy if done so as to achieve extended lymphadenecto‐
my. Also, most of the randomized trials have shown low survival benefits which discourage
surgeons to go for extended lymphadenectomy.
In summary, considering the impact of D2 lymphadenectomy on disease specific survival,
most of the cancer hospitals perform D2 as compared to D1 dissection. National Compre‐
hensive Cancer Network has published its treatment guidelines, according to which D2
node dissection is better than D1 dissection. Considering the higher rates of operative mor‐
tality in randomized trials, the choice of surgery is at the discretion of the surgeon. D2 lym‐
phadenectomy that preserves pancreas and spleen provides superior staging benefit at the
same time avoiding excess morbidity. If splenectomy performed during resection of gastric
tumors not adjacent to or invading the spleen or the pancreatic tail will increase the morbid‐
ity and mortality without improving the survival [61]. Hence splenectomy is not recom‐
mendable unless the tumor has extended directly.
2.32. Adjuvant chemoradiotherapy
It is apt to consider adjuvant radiation therapy as nearly 80 percent of patients who suc‐
cumb to GC would have experienced local recurrence. Also, three randomized trials (Inter‐
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group 0116, CALGB 80101 and ARTIST trials) have shown significant survival benefit for
postoperative combined chemoradiation therapy compared to surgery alone following re‐
section of GC [63].
Neoadjuvant/Perioperative chemotherapy: prior to operating for a locally advanced malig‐
nancy, neoadjuvant therapy if used will help to 'downstage' the disease process. Two of the
three large trials (MAGIC, French FNLCC/FFCD, EORTC trial 40954) compared surgery
alone and surgery with neoadjuvant chemotherapy showed a significant survival benefit for
this approach [62, 64, 65].
2.33. Adjuvant chemotherapy
There are more than 30 trials which compared adjuvant systemic chemotherapy to surgery
alone. The overall results were negative. Few of the trials to name are Japanese S-1 trial,
CLASSIC trial.
2.34. Prognosis
Unless treatment is instituted, the doubling time for EGC is of the order of several years in‐
dicating a very stable biologic state compared to a doubling time of less than a year for ad‐
vanced cancer [66]. A very interesting Nomogram has been developed based on various
clinical and pathological statuses by Kim’s group for predicting the disease-free survival
probability [67]. With the treatment on, the overall five year survival rate is more than 90
percent [68]. According to a Korean study, long term survival rate was 95 percent in patients
without nodal involvement; 88% with one to three nodes involved; 77% with more than 3
nodes involvement.
3. Conclusion
Adenocarcinoma is the commonest type of GC. It is one of the top 10 causes of death in
USA, twice more common in blacks. Infection with H.pylori, consumption of salt-preserved
and smoked foods, achlorhydric stomach are few of the important insults for the develop‐
ment of GC. E-cadherin, a key protein on the cell surface responsible for intercellular con‐
nections, is absent in diffuse type of carcinoma enabling tumor cells to invade and
metastasize. TNM staging is the most widely used system for staging the disease. As there
are no screening tests available for diagnosis of GC, patients usually present in the stage 3 or
4 cancer. Early Gastric Cancer is treated with Endoscopic resection, gastrectomy, antibiotic
therapy to eradicate H.pylori and adjuvant therapies. Surgery is the mainstay of treatment
for invasive GC. Adjuvant chemoradiotherapy is essential as 80% treated cases develop local
recurrence. With the treatment being initiated the prognosis is better as the overall five year
survival rate becomes more than 90 percent.
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